Novo Nordisk (NVO) Stock Analysis: AI Score & Alternative Data
NVO alt-data: revenue climbing, business outlook lagging
Is Novo Nordisk a buy right now? The alternative data says hold. This NVO stock analysis is built on the 25+ alternative data signals AltIndex tracks on Novo Nordisk every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 59/100: a Hold. The stock trades at $47.26 with a $209B market cap.
The bullish side of the 90-day ledger: revenue up 24.0% YoY to $96.8B, web traffic up 16.6% to 717K monthly visits, and Instagram followers up 11.2% to 240K followers. The drag: business outlook fell 7.4% — now 50% of employees are positive, job postings down 5.4% to 386 open roles, and Reddit mentions down 76.9% to 3 a day. That tension is what keeps the score mid-range.
NVO’s broader alt-data profile also covers headcount (62K employees, according to LinkedIn), Facebook followers (777K), and sentiment (85/100). Every signal links to its own page with full history, the NVO technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on NVO is just below.
Novo Nordisk AI Stock Analysis
1. Company Overview Novo Nordisk is one of the world’s leading biopharmaceutical companies, best known for its diabetes and obesity franchises. Its core products include GLP-1 therapies such as Ozempic and Wegovy, which have become central to the company’s growth story.
Analysis generated July 26, 2026.
Recent Novo Nordisk Stock Alerts
|
Novo Nordisk | August 5 Reddit mentions are up by 410% in the last 24h. |
|
Novo Nordisk | August 4 Price is down by -6.4% in the last 24h. |
|
Novo Nordisk | August 1 Reddit mentions are up by 455% in the last 24h. |
|
Novo Nordisk | July 31 Price is down by -8.2% in the last 24h. |
Novo Nordisk Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 717K | 16.6% | |
| Job Posts | 386 | 5.4% | |
| LinkedIn Employees | 62K | 1.6% | |
| Google Trends | 10 | 68.8% | |
| Wikipedia Views | 515 | 37.1% | |
| Employee Recommend | 72 | 1.4% | |
| Business Outlook | 50 | 7.4% | |
| Lobbying Cost | $757K | 0% | |
| Sentiment | 85 | 2.3% | |
| Reddit Mentions | 3 | 76.9% | |
| X Mentions | 69 | 62.7% | |
| Stocktwits Mentions | 703 | 7.6% | |
| News Mentions | 4 | 76.5% | |
| Stocktwits Subscribers | 32K | 1.0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 58K | 1.2% | |
| Instagram Followers | 240K | 11.2% | |
| Youtube Subscribers | 46K | 3.1% | |
| Facebook Followers | 777K | 0% | |
| Facebook Engagement | 23K | 88.9% |
About Novo Nordisk (NVO)
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $47.26 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $209B |
| Year Range | $35 – $62 |
| Dividend Yield | 0% |
| PE Ratio | 11.4 |
| Analyst Rating | 38% buy |
| Industry | Drug Manufacturers |
Latest Novo Nordisk News
View more →
Novo Nordisk A/S Q2 Earnings Call HighlightsAugust 8 - Yahoo Entertainment |
|
 |
Novo Nordisk CEO resets expectations for Wegovy's explosive growthAugust 6 - Biztoc.com |
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings - CNBCAugust 6 - Slashdot.org |
|
 |
Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo NordiskAugust 6 - Adweek |
 |
Novo Nordisk faces a rough patchAugust 6 - Biztoc.com |
Novo Nordisk Earnings & Financial Performance
View all earnings →Novo Nordisk Insider Trading Activity
View all →| No recent insider transactions on file. |
Novo Nordisk Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Lisa McClain |
Oct 22, 25 | Buy | $8K+ |
| Marjorie Taylor Greene |
Oct 21, 25 | Buy | $8K+ |
| Lisa McClain |
Sep 15, 25 | Sell | $8K+ |
| Valerie Hoyle |
Sep 12, 25 | Buy | $8K+ |
| Marjorie Taylor Greene |
Sep 1, 25 | Buy | $8K+ |
Stocks Similar to Novo Nordisk
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
AstrazenecaAZN |
$161.42 0.9% | $250B | 53 |
 |
PfizerPFE |
$26.76 2.1% | $153B | 43 |
 |
Bristol-Myers SquibbBMY |
$64.72 0.9% | $132B | 56 |
 |
SanofiSNY |
$43.46 1.3% | $104B | 56 |
 |
Merck & CompanyMRK |
$128.58 0.2% | $317B | 49 |
Explore Novo Nordisk Data
Frequently Asked Questions: Novo Nordisk (NVO)
Novo Nordisk has an AltIndex AI Score of 59/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
59/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Novo Nordisk (NVO) stock is $47.26 with a market cap of $209B.
As of today, Novo Nordisk’s PE (Price to Earnings) ratio is 11.4.
View the latest Novo Nordisk insider transactions to see recent buying and selling activity by company executives and directors.
Check the Novo Nordisk congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The NVO stock price chart above shows Novo Nordisk’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Novo Nordisk technical analysis for RSI, moving averages, and more.
See the stocks similar to Novo Nordisk section on this page for companies in the same industry ranked by market cap and AI Score.
